Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance

International Journal of Gynecological Cancer

Volumn 15, Issue 4, 2005, Pages 618-623

  Ayhan, A ^a,a   Ertunc, D ^a   Tok, Ekrem C ^a,b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b MERSIN UNIVERSITY   (Turkey)

Author keywords

c Met expression; Epithelial ovarian cancer; Prognosis; Survival

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; PARAFFIN;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MULTIVARIATE ANALYSIS; ONCOGENE C MET; OVARIECTOMY; OVARY CARCINOMA; PARAAORTIC LYMPH NODE; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE;

ADENOCARCINOMA; ADULT; AGED; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 22544464690     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.00117.x     Document Type: Article

References (39)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Omura GA, Brady MF, Homesley HD et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991;9:1138-50.
3. Hoskins WJ, McGuire WP, Brady MF et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with sub-optimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-80.
4. Berchuck A, Olt GJ, Everitt L, Soisson AP, Bast RC Jr, Boyer CM. The role of peptide growth factors in epithelial ovarian cancer. Obstet Gynecol 1990;75:255-62.
5. Hartmann LC, Podratz KC, Keeney GL et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994;12:64-9.
6. Sui L, Dong Y, Ohno M et al. Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors. Gynecol Oncol 2001;83:56-63.
7. Kimmig R, Wimberger P, Hillemanns P, Kapsner T, Caspari C, Hepp H. Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labeled tumor cells. Gynecol Oncol 2002;84:21-31.
8. Goke M, Kanai M, Podolsky DK. Intestinal fibroblasts regulate intestinal epithelial cell proliferation via hepatocyte growth factor. Am J Physiol 1998;274:809-18.
9. Igawa T, Kanda S, Kanetake H et al. Hepatocyte growth factor is a potent mitogen for cultured rabbit renal tubular epithelial cells. Biochem Biophys Res Commun 1991;174:831-8.
10. Paciucci R, Vila MR, Adell T et al. Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met. Am J Pathol 1998;153:201-12.
11. Matsubara Y, Ichinose M, Yahagi N et al. Hepatocyte growth factor activator: a possible regulator of morphogenesis during fetal development of the rat gastrointestinal tract. Biochem Biophys Res Commun 1998;253:477-84.
12. Yo Y, Morishita R, Nakamura S et al. Potential role of hepatocyte growth factor in the maintenance of renal structure: anti-apoptotic action of HGF on epithelial cells. Kidney Int 1998;54:1128-38.
13. Lamszus K, Jin L, Fuchs A et al. Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice. Lab Invest 1997;76:339-53.
14. Medico E, Mongiovi AM, Huff J et al. The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of liver progenitor cells in vitro. Mol Biol Cell 1996;7:495-504.
15. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 1992;189:227-32.
16. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LW. c-Met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 1995;154:293-8.
17. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 1997;25:862-6.
18. Bae-Jump V, Segreti EM, Vandermolen D, Kauma S. Hepatocyte growth factor (HGF) induces invasion of endometrial carcinoma cell lines in vitro. Gynecol Oncol 1999;73:265-72.
19. Scarpino S, Stoppacciaro A, Colarossi C et al. Hepatocyte growth factor (HGF) stimulates tumour invasiveness in papillary carcinoma of the thyroid. J Pathol 1999;189:570-5.
20. Cancer Committee of the International Federation of Gynecology and Obstetrics. Staging announcement. Gynecol Oncol 1989;25:383-5.
21. Serov SF, Scully R, Sobin LH. Histological typing of ovarian tumors. International histological classification of tumors no. 9. Geneva: WHO, 1973:37-8.
22. Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994;73:1882-8.
23. Bauknecht T, Kommoss F, Birmelin G, von Kleist S, Kohler M, Pfleiderer A. Expression analysis of EGF-R and TGFa in human ovarian carcinomas. Anticancer Res 1991;11:1523-8.
24. Hartenbach EM, Olson TA, Goswitz JJ et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 1997;121:169-75.
25. Fracchioli S, Katsaros D, Maggiora P, Di Renzo MF, Massobrio M. Evaluation of Ron and Met proto-oncogene expression in epithelial ovarian tumors [Abstract]. Minerva Ginecol 1999;51:359-64.
26. Di Renzo MF, Olivero M, Katsaros D et al. Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer 1994;58:658-62.
27. Pisters LL, el-Naggar AK, Luo W, Malpica A, Lin SH. c-Met proto-oncogene expression in benign and malignant human renal tissues. J Urol 1997;158:724-8.
28. Wagatsuma S, Konno R, Sato S, Yajima A. Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma. Cancer 1998;82:520-30.
29. Umeki K, Shiota G, Kawasaki H. Clinical significance of c-Met oncogene alterations in human colorectal cancer. Oncology 1999;56:314-21.
30. Nakajima M, Sawada H, Yamada Y et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999;85:1894-902.
31. Ruco LP, Ranalli T, Marzullo A et al. Expression of Met protein in thyroid tumours. J Pathol 1996;180:266-70.
32. Sawatsubashi M, Sasatomi E, Mizokami H, Tokunaga O, Shin T. Expression of c-Met in laryngeal carcinoma. Virchows Arch 1998;432:331-5.
33. Beviglia L, Matsumoto K, Lin CS, Ziober BL, Kramer RH. Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int J Cancer 1997;74:301-9.
34. Ghoussoub RA, Dillon DA, D'Aquila T, Rimm EB, Fearon ER, Rimm DL. Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 1998;82:1513-20.
35. Ichimura E, Maeshima A, Nakajima T, Nakamura T. Expression of c-Met/HGF receptor in human non-small cell lung carcinomas invitro and invivo and its prognostic significance. Jpn J Cancer Res 1996;87:1063-9.
36. Cheng HL, Trink B, Tzai TS et al. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol 2002;20:1544-50.
37. Daveau M, Scotte M, Francois A et al. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog 2003;36:130-41.
38. Qian CN, Guo X, Cao B et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 2002;62:589-96.
39. Baykal C, Ayhan A, Al A, Yuce K, Ayhan A. Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas. Gynecol Oncol 2003;88:123-9.